Anzeige
Mehr »
Lynx Broker
Login
Mittwoch, 16.10.2019 Börsentäglich über 12.000 News von 613 internationalen Medien
Konkurrenz beeindruckt! Bisher noch unentdeckt von Investoren ist die neue Technologie jetzt marktreif! Aktie vor Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0F57T ISIN: JP3475350009 Ticker-Symbol: D4S 
Tradegate
15.10.19
19:25 Uhr
58,50 Euro
+4,50
+8,33 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
DAIICHI SANKYO CO LTD Chart 1 Jahr
5-Tage-Chart
DAIICHI SANKYO CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
56,50
57,50
13:13
57,00
57,50
13:13

Aktuelle News zur DAIICHI SANKYO Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DAIICHI SANKYO Aktien jetzt im kostenlosen Demokonto handeln!
26.09.XFRA DIVIDEND/INTEREST INFORMATION - 27.09.2019 - 7437FOLGENDE WERTPAPIERE WERDEN AM 26.09.2019 CUM DIVIDENDE/ZINSEN UND AM 27.09.2019 EX DIVIDENDE/ZINSEN GEHANDELT. THE PRE-DIVIDEND/INTEREST DAY OF THE FOLLOWING SHARES WILL BE 26.09.2019. THE EX-DIVIDEND/INTEREST...
► Artikel lesen
20.09.Astellas' AML drug wins over CHMP - strengthening lead on Daiichi Sankyo10
10.09.Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo's DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer346- Updated results presented for investigational TROP2 targeting ADC DS-1062 in unselected patients with unresectable advanced NSCLC who are refractory to or have relapsed following...
► Artikel lesen
10.09.Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer359- Late-breaking results presented for U3-1402, a HER3 targeting ADC, in patients with metastatic EGFR mutated, TKI resistant NSCLC - Manageable safety profile reported for U3-1402 with...
► Artikel lesen
09.09.Daiichi Sankyo files marketing application in Japan for breast cancer ADC3
09.09.Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer344- Global regulatory submission for the antibody drug conjugate is based on the pivotal phase 2 DESTINY-Breast01 and phase 1 trials TOKYO, MUNICH and BASKING RIDGE, New Jersey, Sept....
► Artikel lesen
04.09.Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA? (edoxaban) in Patients with Atrial Fibrillation371- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based...
► Artikel lesen
23.08.Daiichi Sankyo Names Chief People Officer3
22.08.Daiichi Sankyo Announces the Presentation of New Data on LIXIANA? (edoxaban) to be Presented at ESC Congress 2019813- Data presentations from ENTRUST-AF PCI and ETNA-AF add to the growing body of scientific evidence from the Edoxaban Clinical Research Programme - First-time presentation of ENTRUST-AF...
► Artikel lesen
22.08.Updated Clinical Results and New Translational Research Data for Daiichi Sankyo's ADCs U3-1402 and DS-1062 to be Presented at the 2019 World Conference on Lung Cancer422-- Late-breaking U3-1402 and DS-1062 results in advanced or metastatic non-small cell lung cancer (NSCLC) to be presented -- New findings on biomarker expression and genomic alterations...
► Artikel lesen
06.08.FDA approves Daiichi Sankyo's Turalio for rare joint tumour7
05.08.Daiichi Sankyo wades deeper into oncology with FDA go-ahead in rare joint cancer2
05.08.Daiichi Sankyo scores landmark FDA OK for rare tumor drug - albeit with restrictions-
05.08.FDA Approves Daiichi Sankyo's TURALIO (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor227- TURALIO is the first and only approved therapy for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not...
► Artikel lesen
02.08.UPDATE 1-U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor2
02.08.U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor1
31.07.Daiichi Sankyo Company reports Q1 results5
31.07.Daiichi Sankyo Q1 Profit Increases83TOKYO (dpa-AFX) - Daiichi Sankyo Co. Ltd. (DSKYF.PK) reported that its first-quarter profit attributable to owners of the company increased by 19.4 billion yen, or 81.0% to 43.3 billion yen...
► Artikel lesen
21.06.Green-lighted in Japan, FDA quickly spurns Daiichi Sankyo's flawed application for AML drug10
21.06.UPDATE 1-FDA declines to approve Daiichi Sankyo's blood cancer treatment7
Seite:  Weiter >>
71 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,1